Wegovy is administered as a once-weekly injection and is approved specifically for weight management
By the fourweek mark, many patients notice some appetite reduction, but others may still be adjusting
The result is fewer side effects than the other GLP-1 agonists, along with more weight loss and better insulin control, Skelley notes
Understanding your genetic profile helps your provider determine whether standard dosing will maximize your weight loss, or if a different compound like tirzepatide might be more effective for your biology
We hope this approval supports increasing access to obesity care in the UK. The pills, which contain semaglutide, are now approved for adults who are obese (BMI of 30 or above) or overweight (BMI of 27-30) and have at least one weight-related health condition
Even a single day at room temperature can begin visible potency loss